ArticleOphthalmology2022
The Association among Blood Pressure, Blood Pressure Medications, and Glaucoma in a Nationwide Electronic Health Records Database.
Article in Ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- The Relevance of Arterial Blood Pressure in the Management of Glaucoma Progression: A Systematic Review.American journal of hypertension · 2024Pooled it
- Beyond intraocular pressure: vascular and metabolic modifiers of optic nerve vulnerability in glaucoma.International ophthalmology · 2026Review
- Role of perfusion-related metrics in visual field progression of primary open-angle and exfoliation glaucoma: a natural language processing approach.Japanese journal of ophthalmology · 2026Article
- Predictors of Glaucoma Conversion in an African Ancestry Cohort: A Longitudinal Study.American journal of ophthalmology · 2025Article
- Epidemiology and risk factors of glaucoma in a comprehensive health screening baseline report from the Gangnam Eye Cohort Study.Scientific reports · 2025Article
- High-Density Lipoproteins Associated with Age-Related Macular Degeneration in the All of Us Research Program.Ophthalmology · 2025Article
- Nationwide cohort study of primary open angle glaucoma risk and cardiovascular factors among in Korean glaucoma suspects.Scientific reports · 2025Article
- Epidemiological variations and trends in glaucoma burden in the Belt and Road countries.BMC ophthalmology · 2024Article
- Blood Pressure Measures and Incident Primary Open-Angle Glaucoma.Investigative ophthalmology & visual science · 2022Article
- Applications of natural language processing in ophthalmology: present and future.Frontiers in medicine · 2022Review
- Association of Blood Pressure and Retinal Nerve Fiber Layer Rates of Thinning in Patients with Moderate to Advanced Glaucoma.Ophthalmology. GlaucomaArticle
- Big data for imaging assessment in glaucoma.Taiwan journal of ophthalmologyReview
- Big data and electronic health records for glaucoma research.Taiwan journal of ophthalmologyReview
- Artificial Intelligence Models to Identify Patients with High Probability of Glaucoma Using Electronic Health Records.Ophthalmology scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
purposeTo measure the association among blood pressure (BP), BP medications, and glaucoma using the All of Us Research Program database.
designA retrospective, longitudinal cohort study leveraging a national electronic health record (EHR) database administered by the National Institutes of Health.
participantsEye patients in the All of Us Research Program database with at least 15 months of follow-up and 1 BP measurement.
methodsUnivariable and multivariable Cox regression models predicted the risk of developing incident open-angle glaucoma (OAG). Mean arterial pressure (MAP) and the number of BP medication classes were entered as time-varying predictors to account for changes over time.
main outcome measuresThe risk of developing incident OAG, as defined by billing diagnosis codes.
resultsOf 20 815 eligible eye patients who qualified for this study, 462 developed OAG. Low BP (MAP < 83.0 mmHg) was associated with increased risk of developing OAG (hazard ratio [HR], 1.32; 95% confidence interval [CI], 1.04-1.67). High BP (MAP > 101.3 mmHg) and the number of BP medication classes were not associated with OAG after adjustment for covariates. Other risk factors associated with OAG included being Black (HR, 3.31, 95% CI, 2.63-4.17), Hispanic or Latino (HR, 2.53, 95% CI, 1.94-3.28), Asian (HR, 2.22, 95% CI, 1.24-3.97), older in age (80+ years, HR, 20.1, 95% CI, 9.10-44.5), and diabetic (HR, 1.32, 95% CI, 1.04-1.67). Female gender was associated with decreased hazard of developing OAG (HR, 0.66, 95% CI, 0.55-0.80). No significant interaction was observed between MAP and the number of BP medications on the risk of developing OAG.
conclusionsWe found that low BP is associated with increased risk of developing OAG in a national longitudinal EHR database. We did not find evidence supporting a differential effect of medically treated and untreated low BP. This study adds to the body of literature implicating vascular dysregulation as a potential etiology for the development of OAG, particularly emphasizing the lack of influence of BP medications on this relationship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.